Atin Tomar | President & CEO
CPL Biologicals | India

Atin Tomar, President & CEO, CPL Biologicals

Atin Tomar is President & CEO of CPL Biologicals Pvt. Ltd., a joint venture company formed between Cadila Pharmaceuticals Limited, India and Novavax Inc, USA in 2009. CPL Biologicals focuses on research & development, manufacturing and commercialization of Vaccines, Biologics and Diagnostics for human health.

Atin brings with him comprehensive experience in Biotechnology industry in the areas of Vaccines and Biologics, globally. Atin’s expertise spans from Process Development, Scale-up, Technology Transfer and Manufacturing Operations to Business Development, Licensing and Commercialization.

Prior to joining CPL Biologicals, Atin was associated with the Biotechnology industry in various roles. He was involved in the development of Biologics/Bio-therapeutics from the early stages of development to commercial manufacturing at Human Genome Sciences Inc., Amgen Inc. and Syngene International Limited (A Biocon Company). At Dr. Reddy’s Laboratories Ltd., MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd. and International Vaccine Institute (IVI) Atin was involved in Business Development & Licensing, Partnerships and Collaborations, Program Management, Alliance Management and Commercialization for Biosimilars and Vaccines.

Atin completed his B.Tech (Hons) in Biotechnology and Biochemical Engineering from the Indian Institute of Technology (IIT) Kharagpur, India, MS in Biological Engineering from the University of Georgia, Athens, USA and Post-Graduate Programme in Management (MBA) in Finance and Strategy & Leadership from the Indian School of Business (ISB), Hyderabad, India.

Appearances:



Conference Day 1 @ 14:20

Sustainability of Vaccines Industry: Coping with pricing pressures

India is supplying more than 60% of the vaccines procured by GAVI. Vaccines in the public market are older and mass manufactured. Due to the cost of production, new vaccines are not able to enter the market. Should local vaccine manufacturers focus on ensuring cheap production of old vaccines for the public market or should they develop new vaccines for their private market instead? This session will explore differences between public & private markets, together with strategies for navigating the public market.
  • Comparing the differences between public and private market in terms of development and production cost
  • Understanding the differences in demands for both markets
  • What are some challenges that are unique to the public market? (E.g. Price pressures from GAVI, WHO)
  • Explore strategies in overcoming these challenges to achieve a sustainable model

back to speakers